AT1

0.00%

2.4¢ atomo diagnostics limited

AT1 FY21 - General Discussion + FA, page-627

First 627 Last

Share
Profile

Follow
Soul13

520 Posts.

93

23/01/21

18:20

Post #: 50399949
Share

Originally posted by Soul13: ↑

COVID-19 Business Performance (FY20)
FY20 sales revenue of $5.4m
•COVID-19 Sales Revenue - $3.4m
NON-COVID Sales=$2m (assuming 500k in each quarter)
•COVID-19 Units Sold – 1.08m
3.4/1.08=$3.15 per device

NG Biotech (France) – high margin OEM contract for France and UK, 1.75m devices ordered to date (FY20)
If I interpreted correctly, the other 670k (1.75m-1.08m) devices sale were made in FY21
which is 670k*$3.15= $ 2.11m

Access Bio has placed an initial order for 259,200 Atomo devices to be used to build inventory of COVID-19 antibody tests in anticipation of US FDA approval.

DIVOC Labs has committed to an initial order of 77,000 units which will become effective upon receipt by DIVOC of regulatory approval of the product for professional use in India.

259200+77000=336200 devices in total* $3.15 = 1.059 m

Given the first quarter, AT1's sales were 2.5m and assuming the orders above turned into sales in the first two quarters.

The minimum amount of sales estimated for Q2 from the given data should be:
$ 2.11m + $1.059 m +$1.0m from Non-COVID side of business (assuming it is same as last year) - $2.5m from Q1 = $1.669m

There are a few other things I would like to know,
Has NG-biotech ordered more from us this quarter? If not, why not given the circumstances in Europe.
Has the other side of the business grown from last year? If so, how much? (given TGA approval for HIV tests, John also said in an interview that the HIV side of the business is doing better. And the success of AT1's partner Lumos)
Has AT1 applied for regulatory approval in SE Asian countries and Brazil? (if I remembered correctly) as they have the exclusive right to sell antibody tests.

PLEASE CORRECT ME IF I'M WRONG, as I do not have any experience in calculating this sort of stuff.

Cheers

Expand

Just a correction, since we don't have approval in India, the sales might not have made given the terms agreed.

So the minimum amount of sales estimated for Q2 from the given data should be:

$ 2.11m + $0.816 m +$1.0m from Non-COVID side of business (assuming it is same as last year) - $2.5m from Q1 = $1.426m

AT1 Price at posting: 30.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

WGX

Westgold sets its sights on top five producer status through merger with Karora

GRX

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

There are more pages in this discussion • 1,807 more messages in this thread...

First 627 Last

Add AT1 (ASX) to my watchlist

(20min delay)
Last 2.4¢		Change 0.000(0.00%)		Mkt cap ! $15.34M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	497908	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.5¢	67200	3

View Market Depth

No.	Vol.	Price($)
3	497908	0.023
6	725023	0.022
4	217292	0.021
2	250000	0.020
1	26316	0.019

Price($)	Vol.	No.
0.025	67200	3
0.026	390045	2
0.027	648550	3
0.028	155890	3
0.029	425248	5

Last trade - 16.12pm 02/08/2024 (20 minute delay)

AT1 (ASX) Chart

Day chart unavailable

AT1 FY21 - General Discussion + FA, page-627

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Westgold sets its sights on top five producer status through merger with Karora

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

AT1 FY21 - General Discussion + FA, page-627

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Westgold sets its sights on top five producer status through merger with Karora

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News